Cereno Scientific presents an updated agenda for the Capital Markets Day October 17th, 2024
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for diseases with high unmet medical needs, today announced an updated agenda for the Capital Markets Day on Thursday October 17, 2024.
The Capital Markets Day will provide an opportunity for investors, analysts, and media to get insights into Cereno’s clinical and preclinical development portfolio and operations as well as its future growth strategy. The program includes presentations by the Cereno Executive Management Team as well as external speakers
The interest for the Capital Markets Day has been high and the event at Posthuset in Stockholm is fully booked. For those not attending on site, there is an opportunity to participate virtually.
Date: October 17
Time: 13:30–16:30 CET
Venue: Online
Register here: https://lnkd.in/djQdTmsY
Aside from the live streaming, a video of the Capital Markets Day presentations will be shared subsequently on Cereno’s website, Youtube and LinkedIn.
|
Time |
Discussion Item |
Speaker |
|
13:30 |
Welcome |
|
|
13:35 |
Introduction to Cereno Scientific |
Sten R. Sörensen CEO, Cereno Scientific |
|
13:50 |
Understanding PAH, a debilitating rare disease
|
Dr. Raymond Benza Network Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City
|
|
14:10 |
Cereno Scientific’s CS1 in PAH |
Dr. Rahul Agrawal,
|
|
14:15 |
Cereno Scientific’s CS1 - Phase IIa trial results |
Dr. Rahul Agrawal, Nicholas Oakes,
|
|
14:40 |
Investigator and patient perspective of CS1-003 trial |
Dr. Jason Guichard
|
|
14:45 |
Next steps for CS1 |
Dr. Rahul Agrawal |
|
14:55 |
Introduction to Fluidda and the innovative Functional Respiratory Imaging technology |
Jan De Backer
|
|
15:05 |
Short break |
|
|
15:15 |
CS014 targeting unmet needs in rare disease IPF |
Dr. Björn Dahlöf,
|
|
15:35 |
CS585 being evaluated in rare diseases
|
Dr. Michael Holinstat Prof. at University of Michigan Medical School; and Director Translation Research, Cereno Scientific
|
|
15:55 |
Cereno Scientific - strategic focus and future outlook |
Sten R. Sörensen CEO, Cereno Scientific |
|
16:10 |
Questions from Audience on site and online |
Moderated by Dr. Rahul Agrawal, CMO and Head of R&D, Cereno Scientific
|
|
16:25 |
Concluding remarks |
Sten R. Sörensen CEO, Cereno Scientific |
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: [email protected]
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: [email protected]
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for diseases with high unmet medical needs. Lead drug candidate, CS1, is an HDAC inhibitor that acts as an epigenetic modulator, with pressure-reducing, reverse-remodeling, anti-fibrotic, anti-inflammatory and anti-thrombotic properties. CS1 is being developed as a disease-modifying treatment for the serious and life-threatening rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. CS1 study data, together with preclinical information, is consistent with reversing pathological remodeling. A collaboration agreement with global healthcare company Abbott allowed Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1 when no comparable alternative therapy options are available. CS1 holds orphan drug designations in both the US and EU. HDAC inhibitor CS014, in Phase I development, is a new chemical entity being developed as a disease-modifying treatment for rare disease Idiopathic Pulmonary Fibrosis (IPF). Preclinical studies of HDAC inhibitors show that these drugs can reverse fibrosis in models of IPF. Studies also show that these drugs prevent the pathological remodeling of pulmonary vessels that ultimately leads to pulmonary hypertension in many IPF patients. Preclinical studies of CS014 have demonstrated an effect on reversal of fibrosis and a dose-dependent beneficial effect on pathological vascular remodeling in an established model of PAH. Together, these findings indicate that CS014 has the potential to address the underlying pathophysiology behind the development of IPF. CS014 has demonstrated, in preclinical studies, the ability to regulate platelet activity, local fibrinolysis, and clot stability, helping to prevent thrombosis without increasing the risk of bleeding. This supports CS014's potential to address key unmet needs in IPF patients. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. A target indication for CS585 is currently being evaluated; rare diseases with high unmet medical needs are being considered. CS014 and CS585 are developed through research collaborations with the University of Michigan. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, [email protected]. More information is on www.cerenoscientific.com.
